Podcast: How Imagion is bringing cancer diagnostics into the 21st century.
“According to Imagion Biosystems (ASX:IBX) CEO, Robert Proulx, advancements in imaging have been slow, with no real progress made for half a century. Imagion is looking to redress that balance and speaks with Finfeed about the cancer diagnostics market, how Imagion is leading the way in bringing the field into the 21st century and why people should seek out early detection, if the feel vulnerable to cancer in any way.”
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority